Germany's Drug Shortages Leave Patients Struggling for Essential Medications in 2025

Drug shortages in Germany have worsened in 2025, with over 1,500 reports of supply problems affecting essential medications. Patients relying on psychotropic drugs, antibiotics, and asthma treatments face ongoing difficulties. Emergency measures have eased some shortages, but confusion persists due to foreign-language packaging on imported substitutes.

The crisis has hit psychotropic medications hardest. Around one million patients received affected drugs in 2024, and shortages have only grown since. Antipsychotics lead the shortages, with 173 reports covering 151 different product codes (PZNs) and lasting an average of 230 days. Antidepressants follow closely, with 130 shortage reports affecting 126 PZNs and an average disruption of 107 days.

Antibiotics remain another critical area, logging 85 shortage reports across 78 PZNs, with each shortage lasting about 122 days. Lipid-lowering agents also face persistent issues, with 89 reports affecting 80 PZNs and an average shortage duration of 156 days. Salbutamol and antiepileptic drugs add to the strain, as alternatives are scarce.

Germany's reliance on Asian manufacturing leaves its supply chain exposed to global disruptions. Industry experts now call for an early-warning system to alert stakeholders about production failures abroad. This would help pharmacies and hospitals prepare for potential shortages before they escalate.

Emergency imports have provided temporary relief for some drugs, including salbutamol. However, non-German labels on these imports create confusion for patients and pharmacists, complicating safe usage.

The shortages have led to 1,514 reports covering 1,041 distinct supply bottlenecks in 2025. Patients and healthcare providers continue to navigate gaps in medication availability, particularly for life-saving treatments. Without systemic changes, including better early warnings and diversified supply chains, the risk of prolonged shortages remains high.